Search results for "acute heart failure"

showing 10 items of 25 documents

Data for: Impact of pre-hospital renal function on the detection of acute kidney injury in acute decompensated heart failure

2021

Database THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOVE

Acute Heart FailureInformationSystems_DATABASEMANAGEMENTOtherInterdisciplinary sciencesAcute Kidney Injury
researchProduct

Early cardiac unloading with ImpellaCP™ in acute myocardial infarction with ventricular septal defect

2020

Abstract Despite a relative contraindication, mechanical support with Impella™ left ventricular assist device has already been described for ischaemic ventricular septal defect treatment, either as a bridge to surgery, as intraoperative mechanical haemodynamic support, or to ensure intraprocedural haemodynamic stability during device closure. We describe two cases of ventricular septal defect complicating acute myocardial infarction, where the percutaneous ImpellaCP was implanted early (differently than previously described) with the aim of preventing haemodynamic instability, while deferring surgical repair. We present a report of haemodynamic, echocardiographic, biochemical, and clinical …

Heart Septal Defects Ventricularmedicine.medical_specialtyPercutaneousAcute myocardial infarction mechanical complicationmedicine.medical_treatmentMyocardial InfarctionCase ReportLeft ventricular assist device610 Medicine & health030204 cardiovascular system & hematologyVentricular septal defectImpella11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicine03 medical and health sciences0302 clinical medicineInternal medicineDiseases of the circulatory (Cardiovascular) systemMedicineHumans030212 general & internal medicineMyocardial infarctioncardiovascular diseasesContraindicationImpellaSurgical repairbusiness.industryHemodynamicsAcute heart failureHeartPerioperativemedicine.diseaseRC666-701Heart failureVentricular assist deviceCardiologyHeart-Assist DevicesCardiology and Cardiovascular Medicinebusiness
researchProduct

B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure

2019

Aims In acute heart failure (AHF), relationships between changes in B-type natriuretic peptide (BNP) and worsening renal function (WRF) and its prognostic implications have not been fully determined. We investigated the relationship between WRF and a decrease in BNP with in-hospital and 1-year mortality in AHF. Methods and results The Acute Kidney Injury NGAL Evaluation of Symptomatic heart faIlure Study (AKINESIS) was a prospective, international, multicentre study of AHF patients. Severe WRF (sWRF) was a sustained increase of >= 44.2 mu mol/L (0.5 mg/dL) or >= 50% in creatinine, non-severe WRF (nsWRF) was a non-sustained increase of >= 26.5 mu mol/L (0.3 mg/dL) or >= 50% in cr…

InotropeMaleTime Factorsmedicine.medical_treatmentWorsening renal function030204 cardiovascular system & hematologyKidneyKidney Function TestsRISK STRATIFICATIONchemistry.chemical_compound0302 clinical medicineAcute heart failure; B-type natriuretic peptide; Mortality; Worsening renal function; Acute Disease; Acute Kidney Injury; Aged; Biomarkers; Creatinine; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Kidney Function Tests; Male; Natriuretic Peptide Brain; Prognosis; Prospective Studies; Time FactorsNatriuretic Peptide BrainNatriuretic peptideProspective StudiesDISCHARGEAcute kidney injuryBrainAcute Kidney InjuryPrognosis3. Good healthDERIVATIONHOSPITALIZATIONCreatinineAcute DiseaseCardiologyDisease ProgressionFemaleCardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsGlomerular Filtration RateVENOUS CONGESTIONmedicine.medical_specialtymedicine.drug_classRenal functionPRESSUREVALIDATION03 medical and health sciencesNatriuretic PeptideInternal medicinemedicineHumansRenal replacement therapycardiovascular diseasesAgedMechanical ventilationHeart FailureCreatininebusiness.industryMORTALITYAcute heart failuremedicine.diseasechemistryB-type natriuretic peptideHeart failurebusinessBiomarkersFollow-Up Studies
researchProduct

Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure

2021

Aims Improving renal function (IRF) is paradoxically associated with worse outcomes in acute heart failure (AHF), but outcomes may differ based on response to decongestion. We explored if the relationship of IRF with mortality in hospitalized AHF patients differs based on successful decongestion.Methods and results We evaluated 760 AHF patients from AKINESIS for the relationship between IRF, change in B-type natriuretic peptide (BNP), and 1-year mortality. IRF was defined as a >= 20% increase in estimated glomerular filtration rate (eGFR) relative to admission. Adequate decongestion was defined as a >= 40% decrease in last measured BNP relative to admission. IRF occurred in 22% of pat…

InotropeMalemedicine.medical_specialtymedicine.drug_classRenal function030204 cardiovascular system & hematologyKidney03 medical and health sciences0302 clinical medicineKidney functionNatriuretic PeptideB&#8208Internal medicineNatriuretic Peptide BrainNatriuretic peptidemedicinetype natriuretic peptideHumansBlood urea nitrogenAgedHeart Failurebusiness.industryAcute heart failure; B-type natriuretic peptide; Congestion; Kidney function; Prognosis; Acute Disease; Aged; Biomarkers; Humans; Kidney; Male; Natriuretic Peptide Brain; Prognosis; Heart FailureHazard ratioBrainAcute heart failuremedicine.diseasePrognosisConfidence interval3. Good healthBlood pressureB-type natriuretic peptideHeart failureAcute DiseaseCardiologyCongestionCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean Journal of Heart Failure
researchProduct

Do the current guidelines for heart failure diagnosis and treatment fit with clinical complexity?

2022

Heart failure (HF) is a clinical syndrome defined by specific symptoms and signs due to structural and/or functional heart abnormalities, which lead to inadequate cardiac output and/or increased intraventricular filling pressure. Importantly, HF becomes progressively a multisystemic disease. However, in August 2021, the European Society of Cardiology published the new Guidelines for the diagnosis and treatment of acute and chronic HF, according to which the left ventricular ejection fraction (LVEF) continues to represent the pivotal parameter for HF patients’ evaluation, risk stratification and therapeutic management despite its limitations are well known. Indeed, HF has a complex pathophys…

Left ventricular ejection fractiontherapyacute heart failureheart failure left ventricular ejection fraction New York Heart Association classification acute heart failure chronic heart failure phenotypes pathophysiology therapyAcute heart failure; Chronic heart failure; Heart failure; Left ventricular ejection fraction; New York Heart Association classification; Pathophysiology; Phenotypes; TherapyRphenotypesAcute heart failureheart failureHeart failureleft ventricular ejection fractionGeneral MedicineNew York Heart Association classificationPathophysiologyChronic heart failurechronic heart failurePhenotypesMedicineTherapyacute heart failure; chronic heart failure; heart failure; left ventricular ejection fraction; new york heart association classification; pathophysiology; phenotypes; therapypathophysiology
researchProduct

Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality

2018

Background: The prognostic value of long-term potassium monitoring and dynamics in heart failure has not been characterized completely. We sought to determine the association between serum potassium values collected at follow-up with all-cause mortality in a prospective and consecutive cohort of patients discharged from a previous acute heart failure admission. Methods: Serum potassium was measured at every physician-patient encounter, including hospital admissions and ambulatory settings. The multivariable-adjusted association of serum potassium with mortality was assessed by using comprehensive state-of-the-art regression methods that can accommodate time-dependent exposure modeling. Res…

MaleHyperkalemiaPotassiumheart failure030204 cardiovascular system & hematology0302 clinical medicinecohort studiesCause of DeathRisk of mortalitylongitudinal studies030212 general & internal medicineProspective StudiesAged 80 and overpotassiumHazard ratioMiddle AgedPrognosisHypokalemiaCardiologyFemalemedicine.symptomCardiology and Cardiovascular Medicineacute heart failure; heart failure; hyperkalemia; hypokalemia; longitudinal cohort study; mortality; potassiumGlomerular Filtration RateRiskmedicine.medical_specialtyacute heart failurechemistry.chemical_elementHypokalemia03 medical and health sciencesPhysiology (medical)Internal medicinehypokalemiamedicineHumansIntensive care medicineAgedProportional Hazards ModelsHeart Failurebusiness.industryProportional hazards modellongitudinal cohort studyhyperkalemiamedicine.diseasemortalitySurvival AnalysisConfidence intervalchemistryHeart failurePotassiumPotentiometryHyperkalemiabusiness
researchProduct

Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Find…

2019

ABSTRACT Background: Worsening renal function (WRF) during acute heart failure (AHF) occurs frequently and has been associated with adverse outcomes, though this association has been questioned. WRF is now evaluated by function and injury. We evaluated whether urine neutrophil gelatinase-associated lipocalin (uNGAL) is superior to creatinine for prediction and prognosis of WRF in patients with AHF. Methods and Results: We performed a multicenter, international, prospective cohort of patients with AHF requiring IV diuretics. The primary outcome was whether uNGAL predicted development of WRF, defined as a sustained increase in creatinine of 0.5 mg/dL or ≥50% above first value or initiation of…

MalePROGNOSISInternationalitymedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidneyKidney Function TestsGastroenterologyTHERAPYCohort Studieschemistry.chemical_compound0302 clinical medicine030212 general & internal medicineProspective StudiesProspective cohort studyDAMAGERISKAged 80 and overAcute kidney injuryIMPAIRMENTAcute Kidney InjuryMiddle Aged3. Good healthHospitalizationbiomarkerAcute heart failure; biomarker; worsening renal functionFemaleCardiology and Cardiovascular MedicineGlomerular Filtration Ratemedicine.medical_specialtyRenal functionDIAGNOSIS03 medical and health sciencesLipocalin-2Internal medicineSTRATIFICATIONmedicineMANAGEMENTHumansRenal replacement therapyAdverse effectAgedHeart FailureCreatininebusiness.industryMORTALITYAcute heart failuremedicine.diseasechemistryHeart failureworsening renal functionbusinessBiomarkersJournal of cardiac failure
researchProduct

Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure

2015

AIM:Galectin-3 (Gal-3) and carbohydrate antigen 125 (CA125) have emerged as robust prognostic biomarkers in heart failure. Experimental data have also suggested a potential molecular interaction between CA125 and Gal-3; however, the biological and clinical relevance of this interaction is still uncertain. We sought to evaluate, in patients admitted for acute heart failure, the association between plasma Gal-3 with all-cause mortality and the risk for rehospitalizations among high and low levels of CA125. METHODS AND RESULTS: We included 264 consecutive patients admitted for acute heart failure to the Cardiology Department in a third-level center. Both biomarkers were measured on admission. …

Maleendocrine system diseasesGalectin 3lcsh:MedicineRisk FactorsBlood plasmaANTIGEN CARBOHYDRATE 125lcsh:ScienceAged 80 and overMultidisciplinaryca125Mortality rateBlood Proteins//purl.org/becyt/ford/3.1 [https]Middle AgedPrognosisMedicina BásicaGalectin-3Female//purl.org/becyt/ford/3 [https]Research Articlemedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDcontributesGalectinsInmunologíaPatient ReadmissionAntigenInternal medicinemedicineHumanssurfaceClinical significanceIn patientIntensive care medicineAgedProportional Hazards ModelsHeart FailureGALECTIN-3business.industryProportional hazards modellcsh:Rassociationmedicine.diseaseACUTE HEART FAILUREstatin therapyinflammationCA-125 AntigenHeart failurecellslcsh:QbusinessBiomarkersFollow-Up Studies
researchProduct

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

2020

BACKGROUND: The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal function in patients with acute heart failure and renal dysfunction at presentation. METHODS: This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-gui…

Maleendocrine system diseasesPREDICTIONmedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidney Function TestsCONGESTIONBiomarker guided-therapy0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic peptideMedicineRenal Insufficiency030212 general & internal medicinePrecision MedicineANTIGEN CARBOHYDRATE 125Aged 80 and overFurosemideGeneral MedicineDiuretic treatmentEUROPEAN-SOCIETYClinical trialFemaleTRIALmedicine.drugmedicine.medical_specialtyRenal failureSTRATEGIESmedicine.drug_classUrologyRenal function03 medical and health sciencesHumansIn patientAgedHeart FailureSERUM CREATININENATRIURETIC PEPTIDEbusiness.industryMORTALITYMembrane ProteinsAcute heart failuremedicine.diseaseClinical trialCarbohydrate antigen 125CA-125 AntigenHeart failureDiuretic treatmentDiureticbusinessCARDIORENAL SYNDROME
researchProduct

Validity of the Seattle Heart Failure Model after heart failure hospitalization.

2019

Abstract Aims Heart failure hospitalization is a sentinel event associated with increased mortality risk. Whether long‐term heart failure risk models such as the Seattle Heart Failure Model (SHFM) accurately assess risk in the post‐hospital setting is unknown. Methods and results The SHFM was applied to a cohort of 2242 consecutive patients (50% women; mean age 73) on discharge after acute heart failure hospitalization and analysed for the primary endpoint of all‐cause mortality. Model discrimination and calibration were assessed. Direct patient‐level comparison between our study cohort and the original SHFM cohorts was also performed to confirm and quantify the degree and extent of increas…

Malemedicine.medical_specialty030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsSeattle Heart Failure ModelInternal medicineOriginal Research ArticlesClinical endpointmedicineHumansIn patient030212 general & internal medicineOriginal Research ArticleHospital dischargeMortality riskAgedAged 80 and overHeart FailureModels StatisticalReceiver operating characteristicbusiness.industryReproducibility of ResultsAcute heart failureMean ageAfter dischargeMiddle Agedmedicine.diseaseHospitalizationHeart failureAmbulatoryCohortCardiologyFemaleCardiology and Cardiovascular MedicinebusinessESC heart failure
researchProduct